FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:985-993 March 5, 2009 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Wenzel, S. E. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

ABSTRACT

Background Eosinophilic inflammation, which may be a consequence of interleukin-5 action, is a characteristic feature of some forms of asthma. However, in three previous clinical trials involving patients with asthma, blockade of this cytokine did not result in a significant improvement in outcomes. We studied the prednisone-sparing effect of mepolizumab, a monoclonal antibody against interleukin-5, in a rare subgroup of patients who have sputum eosinophilia and airway symptoms despite continued treatment with prednisone. Secondary objectives were to examine its effect on the number of eosinophils in sputum and blood, symptoms, and airflow limitation.

Methods In this randomized, double-blind, parallel-group trial involving patients with persistent sputum eosinophilia and symptoms despite prednisone treatment, we assigned 9 patients to receive mepolizumab (administered in five monthly infusions of 750 mg each) and 11 patients to receive placebo.

Results There were 12 asthma exacerbations in 10 patients who received placebo, 9 of whom had sputum eosinophilia at the time of exacerbation. In comparison, only one patient who received mepolizumab had an asthma exacerbation, and this episode was not associated with sputum eosinophilia (P=0.002). Patients who received mepolizumab were able to reduce their prednisone dose by a mean (±SD) of 83.8±33.4% of their maximum possible dose, as compared with 47.7±40.5% in the placebo group (P=0.04). The use of mepolizumab was associated with a significant decrease in the number of sputum and blood eosinophils. Improvements in eosinophil numbers, asthma control, and forced expiratory volume in 1 second were maintained for 8 weeks after the last infusion. There were no serious adverse events.

Conclusions Mepolizumab reduced the number of blood and sputum eosinophils and allowed prednisone sparing in patients who had asthma with sputum eosinophilia despite prednisone treatment. (ClinicalTrials.gov number, NCT00292877 [ClinicalTrials.gov] .)

Source Information

From the Firestone Institute for Respiratory Health, St. Joseph's Healthcare and Department of Medicine, McMaster University, Hamilton, ON, Canada.

Address reprint requests to Dr. Nair at the Firestone Institute for Respiratory Health, St. Joseph's Healthcare, 50 Charlton Ave., E., Hamilton, ON L8N 4A6, Canada, or at parames{at}mcmaster.ca.

Full Text of this Article

This article has been cited by other articles:

• Barnes, P. J. (2009). The Cytokine Network in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Cell Mol. Bio. 41: 631-638 [Abstract] [Full Text]  
• Kouro, T., Takatsu, K. (2009). IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 21: 1303-1309 [Abstract] [Full Text]  
• Kottyan, L. C., Collier, A. R., Cao, K. H., Niese, K. A., Hedgebeth, M., Radu, C. G., Witte, O. N., Khurana Hershey, G. K., Rothenberg, M. E., Zimmermann, N. (2009). Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner. Blood 114: 2774-2782 [Abstract] [Full Text]  
• Dyer, K. D., Percopo, C. M., Fischer, E. R., Gabryszewski, S. J., Rosenberg, H. F. (2009). Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood 114: 2649-2656 [Abstract] [Full Text]  
• Flaherty, K. R. (2009). Clinical Year in Review IV: Pediatric Pulmonary and Critical Care, Cystic Fibrosis, Asthma, and Pleural Disease. Proc Am Thorac Soc 6: 506-511 [Full Text]  
• Siddiqui, S., Brightling, C. (2009). Magic Bullets: The New Goal for Asthma. Am. J. Respir. Crit. Care Med. 180: 383-384 [Full Text]  
• Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., Fahy, J. V. (2009). T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma. Am. J. Respir. Crit. Care Med. 180: 388-395 [Abstract] [Full Text]  
• Hercus, T. R., Thomas, D., Guthridge, M. A., Ekert, P. G., King-Scott, J., Parker, M. W., Lopez, A. F. (2009). The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 114: 1289-1298 [Abstract] [Full Text]  
• Verbout, N. G., Jacoby, D. B., Gleich, G. J., Fryer, A. D. (2009). Atropine-enhanced, antigen challenge-induced airway hyperreactivity in guinea pigs is mediated by eosinophils and nerve growth factor. Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L228-L237 [Abstract] [Full Text]  
• Zarogiannis, S., Gourgoulianis, K. I., Kostikas, K., Szczeklik, A., Gleich, G. J., Pavord, I. D., Wardlaw, A. J., Haldar, P., Nair, P., Hargreave, F. E., O'Byrne, P., Wenzel, S. E. (2009). Anti-Interleukin-5 Therapy and Severe Asthma. NEJM 360: 2576-2578 [Full Text]  
• Rust, G., Hilmy, N. M., Farel, R. M., Fanta, C. H. (2009). Drug Therapy for Asthma. NEJM 360: 2578-2579 [Full Text]  
• Humbert, M. (2009). Biologics in severe difficult-to-treat asthma: find the right niche!. ERR 18: 51-53 [Full Text]  
• Gaga, M., Zervas, E., Chanez, P. (2009). Update on severe asthma: what we know and what we need. ERR 18: 58-65 [Full Text]  
• (2009). All you need to read in the other general journals. BMJ 338: b963-b963 [Full Text]  
• Wenzel, S. E. (2009). Eosinophils in Asthma -- Closing the Loop or Opening the Door?. NEJM 360: 1026-1028 [Full Text]